Oh dear, how sad, never mind

AstraZeneca sales hit hard by generic competition

By Ben Hirschler

LONDON | Thu Jul 26, 2012 2:59am EDT

(Reuters) - AstraZeneca's sales tumbled 21 percent in the second quarter, punished by generic competition to its best-selling antipsychotic medicine Seroquel and pressure on health spending in Europe.

With patent losses rapidly eroding revenue and few new drugs to replace them, Britain's second-biggest drugmaker is throwing itself into deal-making to bolster the pipeline, following the early exit of its chief executive at the end of May

http://www.reuters.com/article/2012/07/26/us-astrazeneca-earnings-idUSBRE86P07K20120726?feedType=RSS&feedName=healthNews&utm_source=twitterfeed&utm_medium=twitter&utm_campaign=Feed%3A+reuters%2FhealthNews+%28Reuters+Health+News%29.